In this randomized clinical trial, the addition of metformin to concurrent chemoradiation was well tolerated but did not improve survival among patients with unresectable stage III NSCLC. ClinicalTrials.gov Identifier: NCT02186847 READ ARTICLE
JAMA: Journal of American Medical Association DOI:10.1001/jamaoncol.2021.2318
Authors: Heath Skinner, MD,PhD; Chen Hu, PhD; Theodoros Tsakiridis, MD, PhD; Rafael Santana-Davila, MD; Bo Lu, MD; Jeremy J. Erasmus, MD; Anthony J. Doemer, MS; Gregory M. M. Videtic, MD; James Coster, MD; Alex Xuezhong Yang, MD; Richard Y. Lee, MD, PhD; Maria Werner-Wasik, MD; Philip E. Schaner, MD, PhD; Steven E. McCormack, MD; Benjamin T. Esparaz, MD; Ronald C. McGarry, MD,PhD; Jose Bazan, MD; Timothy Struve, MD; Rebecca Paulus, BS and Jeffrey D. Bradley, MD